164 related articles for article (PubMed ID: 11600377)
1. New model of oropharyngeal candidiasis in mice.
Kamai Y; Kubota M; Kamai Y; Hosokawa T; Fukuoka T; Filler SG
Antimicrob Agents Chemother; 2001 Nov; 45(11):3195-7. PubMed ID: 11600377
[TBL] [Abstract][Full Text] [Related]
2. Mouse model of oropharyngeal candidiasis.
Solis NV; Filler SG
Nat Protoc; 2012 Mar; 7(4):637-42. PubMed ID: 22402633
[TBL] [Abstract][Full Text] [Related]
3. [Experimental oral candidiasis in healthy and immunocompromised BALB/c mice].
Karaman M; Kiray M; Bayrakal V; Bağrıyanık HA; Yılmaz O; Bahar IH
Mikrobiyol Bul; 2011 Apr; 45(2):336-43. PubMed ID: 21644077
[TBL] [Abstract][Full Text] [Related]
4. Antifungal activities of two new azasordarins, GW471552 and GW471558, in experimental models of oral and vulvovaginal candidiasis in immunosuppressed rats.
Martinez A; Ferrer S; Santos I; Jimenez E; Sparrowe J; Regadera J; De Las Heras FG; Gargallo-Viola D
Antimicrob Agents Chemother; 2001 Dec; 45(12):3304-9. PubMed ID: 11709301
[TBL] [Abstract][Full Text] [Related]
5. Comparison between bioluminescence imaging technique and CFU count for the study of oropharyngeal candidiasis in mice.
Gabrielli E; Roselletti E; Luciano E; Sabbatini S; Mosci P; Pericolini E
Cytometry A; 2015 May; 87(5):428-36. PubMed ID: 25820122
[TBL] [Abstract][Full Text] [Related]
6. Models hosts for the study of oral candidiasis.
Junqueira JC
Adv Exp Med Biol; 2012; 710():95-105. PubMed ID: 22127889
[TBL] [Abstract][Full Text] [Related]
7. Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis.
Petraitis V; Petraitiene R; Groll AH; Sein T; Schaufele RL; Lyman CA; Francesconi A; Bacher J; Piscitelli SC; Walsh TJ
Antimicrob Agents Chemother; 2001 Feb; 45(2):471-9. PubMed ID: 11158743
[TBL] [Abstract][Full Text] [Related]
8. Candida dubliniensis in radiation-induced oropharyngeal candidiasis.
Redding SW; Bailey CW; Lopez-Ribot JL; Kirkpatrick WR; Fothergill AW; Rinaldi MG; Patterson TF
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 Jun; 91(6):659-62. PubMed ID: 11402278
[TBL] [Abstract][Full Text] [Related]
9. The role of yeasts other than Candida albicans in oropharyngeal candidiasis.
Redding SW
Curr Opin Infect Dis; 2001 Dec; 14(6):673-7. PubMed ID: 11964883
[TBL] [Abstract][Full Text] [Related]
10. [Oropharyngeal candidiasis and radiotherapy].
Pinel B; Cassou-Mounat T; Bensadoun RJ
Cancer Radiother; 2012 May; 16(3):222-9. PubMed ID: 22537826
[TBL] [Abstract][Full Text] [Related]
11. Pathological analysis of the Candida albicans-infected tongue tissues of a murine oral candidiasis model in the early infection stage.
Okada M; Hisajima T; Ishibashi H; Miyasaka T; Abe S; Satoh T
Arch Oral Biol; 2013 Apr; 58(4):444-50. PubMed ID: 23092606
[TBL] [Abstract][Full Text] [Related]
12. A novel murine model of pharyngeal candidiasis with local symptoms characteristic of pharyngeal thrush produced by using an inhaled corticosteroid.
Hu W; Ninomiya K; Ishibashi H; Maruyama N; Oshima H; Yamaguchi H; Abe S
Med Mycol; 2007 Mar; 45(2):143-8. PubMed ID: 17365650
[TBL] [Abstract][Full Text] [Related]
13. Perillaldehyde: A promising antifungal agent to treat oropharyngeal candidiasis.
Chen L; Qu S; Yang K; Liu M; Li YX; Keller NP; Zeng X; Tian J
Biochem Pharmacol; 2020 Oct; 180():114201. PubMed ID: 32822688
[TBL] [Abstract][Full Text] [Related]
14. A novel bioluminescence mouse model for monitoring oropharyngeal candidiasis in mice.
Mosci P; Pericolini E; Gabrielli E; Kenno S; Perito S; Bistoni F; d'Enfert C; Vecchiarelli A
Virulence; 2013 Apr; 4(3):250-4. PubMed ID: 23334179
[TBL] [Abstract][Full Text] [Related]
15. Antifungal efficacy of GM237354, a sordarin derivative, in experimental oral candidiasis in immunosuppressed rats.
Martinez A; Regadera J; Jimenez E; Santos I; Gargallo-Viola D
Antimicrob Agents Chemother; 2001 Apr; 45(4):1008-13. PubMed ID: 11257009
[TBL] [Abstract][Full Text] [Related]
16. Combination of Estrogen and Immunosuppressive Agents to Establish a Mouse Model of Candidiasis with Concurrent Oral and Vaginal Mucosal Infection.
Wang L; Wang C; Mei H; Shen Y; Lv G; Zeng R; Zhan P; Li D; Liu W
Mycopathologia; 2016 Feb; 181(1-2):29-39. PubMed ID: 26404163
[TBL] [Abstract][Full Text] [Related]
17. A reevaluation of nystatin in prophylaxis and treatment of oropharyngeal candidiasis.
Alvarez Alvarez ME; Sánchez-Sousa A; Baquero F
Rev Esp Quimioter; 1998 Dec; 11(4):295-315. PubMed ID: 9990144
[TBL] [Abstract][Full Text] [Related]
18. N-acetylglucosamine increases symptoms and fungal burden in a murine model of oral candidiasis.
Ishijima SA; Hayama K; Takahashi M; Holmes AR; Cannon RD; Abe S
Med Mycol; 2012 Apr; 50(3):252-8. PubMed ID: 21859389
[TBL] [Abstract][Full Text] [Related]
19. Effects of oral inoculation of Candida albicans in tetracycline-treated rats.
Russell C; Jones JH
J Med Microbiol; 1973 Aug; 6(3):275-9. PubMed ID: 4580060
[No Abstract] [Full Text] [Related]
20. A D-octapeptide drug efflux pump inhibitor acts synergistically with azoles in a murine oral candidiasis infection model.
Hayama K; Ishibashi H; Ishijima SA; Niimi K; Tansho S; Ono Y; Monk BC; Holmes AR; Harding DR; Cannon RD; Abe S
FEMS Microbiol Lett; 2012 Mar; 328(2):130-7. PubMed ID: 22211961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
